Navigation Links
Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
Date:11/15/2012

rty with expertise in clinical trial information technology and investigator community management. 

Janssen Research & Development, LLC
Janssen Research & Development, LLC (Janssen), is one of the Janssen Pharmaceutical Companies. Janssen is headquartered in Raritan, N.J. and has facilities in Europe, the United States and Asia. Janssen is leveraging drug discovery and drug development in a variety of therapeutic areas, including Neuroscience, Oncology, Immunology, Infectious Diseases, and Cardiovascular and Metabolism to address unmet medical needs worldwide.  

Janssen Healthcare Innovation and Clinical Trial Innovation
Janssen Healthcare Innovation (JHI) is an entrepreneurial team within Janssen Research & Development. Through collaborations, JHI is developing products and services to deliver high-quality, cost-effective healthcare. JHI's Clinical Trial Innovation team is focused on identifying and testing novel approaches, processes, technologies, and best practices that have the potential to reduce trial set up and execution cycle times, and reduce cost. For more information, go to: www.janssenhealthcareinnovation.com.

Forward Looking Statement
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technolog
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
10. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
11. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  On July 31, ... to Congress that it is moving forward to regulate ... the minutes until laboratories throughout the U.S. will need ... Although some medical laboratories may subscribe to the ... FDA to put guidelines in place, it,s widely acknowledged ...
(Date:9/2/2014)... 2, 2014  Reportlinker.com announces that a new market ... Chinese and Taiwanese Markets for Minimally Invasive Spinal ... The market for MIS spinal devices in ... is growing at a fast pace, albeit at different ... happening in China , where MIS ...
(Date:9/2/2014)... The Pharmaceutical Care Management Association (PCMA), the ... filed a lawsuit in Iowa ... law that restricts tools used by PBMs ... and consumers.  The law—HF 2297—forces PBMs ... use of Maximum Allowable Cost (MAC) lists that keep ...
Breaking Medicine Technology:FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 3Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 2Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 3Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 4Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 5Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 6Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 7Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 8Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 9Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2
... Double-Blind Study Targets Biomarker-Defined Population, BERKELEY ... GNTA ) announced that the first ... Phase 3 trial of Genasense,(oblimersen sodium) Injection ... is a randomized, double-blind, placebo-controlled study in ...
... Editor-in-Chief of New Brain Stimulation Journal, CHARLESTON, ... (MUSC) today announced the results of a functional ... Nerve Stimulation) Therapy(TM),for patients with treatment-resistant depression (TRD). ... MUSC Department of Psychiatry,appears in the August 2007 ...
Cached Medicine Technology:Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression 2New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression 3
(Date:9/2/2014)... 2014 Becker's Healthcare is excited ... Program on October 23-25, 2014 at the Swissotel ... - The Business and Operations of ASCs brings ... continuing education, networking events, and an exhibit hall ... Outstanding educational offerings throughout the three-day event, The ...
(Date:9/2/2014)... BOSTON (September 2, 2014 4 pm EDT): In a ... American Medical Association , a team of Boston researchers ... improve dietary quality in the United States. The researchers ... at Tufts University, Harvard University and Boston Children,s Hospital ... subsidizing healthier foods could both help people make meaningful ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Cloud Medical ... of “Cloud Based” Medical Practice Business Operations solutions and ... of Digital Cyber Security solutions for all industries announced ... on the trading floor of the CME in Chicago ... DeLaGarza stated that we are very proud of the ...
(Date:9/2/2014)... by radiation therapy survived as long as patients ... study conducted by researchers at the Stanford University ... of California. , The comprehensive analysis of nearly ... first to directly compare survival rates following the ... removal of both breasts), unilateral mastectomy (the removal ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Medex ... location of their corporate headquarters in Coral Springs, Fla. ... have exceeded our business development objectives for the 2014 ... Neil Herbst. “Our industry has requested a higher level ... utilization reviews. Medex has delivered, and the industry has ...
Breaking Medicine News(10 mins):Health News:Becker's Healthcare Announces Ambulatory Surgery Center Educational Program 2Health News:Becker's Healthcare Announces Ambulatory Surgery Center Educational Program 3Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 2Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 3Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 4Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2
... Nov. 25 Thanksgiving meals will be delivered to approximately ... to Faith In Action/Volunteer Action for Aging, a program operated ... Plan. For more than 17 years these organizations have gathered ... in need in Long Beach, Lakewood, Signal Hill, South Bay, ...
... LOS ANGELES, Nov. 25 The Black AIDS Institute recently ... 2010. , The new Board Members are a highly diverse ... government health programs, editorial, and business entrepreneurship. The Board also ... heterosexual and gay Black men and women, some living with ...
... Broad Political Endorsements, Business, and Press Join Effort to ... again, the National Bipolar Foundation and the MedicAlert Foundation receive ... now being widely accepted as a preventive health care measure ... proclamation of endorsement via Federal Express Priority Mail from the ...
... have found evidence of a statistically significant survival ... receptor (ER)-positive tumors had high levels of phosphorylation ... a brief communication published online November 25 in ... . Approximately 50% of breast carcinomas are ...
... pressure? This simple question has been the focus of ... High Blood Pressure in Mice & Men, Does stress increase ... of intense research for many years. Now new research ... novel gene, phosducin, and the blood pressure response to stress ...
... Rituximab, already used to fight rheumatoid arthritis, could help ... (HealthDay News) -- A drug commonly used to treat ... promise in helping patients newly diagnosed with type 1 ... producing some of their own insulin, even though the ...
Cached Medicine News:Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 4Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
Blunt tipped forceps with small, slightly rounded tips angled perpendicular to the shaft. For grasping peripheral membranes....
... As a pioneer in the design and ... extraction of viscous fluids, D.O.R.C. is pleased ... combination of injection and extraction in one ... controlled injection of viscous fluids, such as ...
... both 96- and 384-well plates and ... Washer. As a self contained and ... full control of precise fluidic delivery ... simple squeeze bottle to the full ...
The EL401 Manual Plate/Strip Washer accommodates all 96-well microplates and microwell strips. The unique alignment mechanism allows quick and accurate positioning of the 8- or 12-channel manifold ab...
Medicine Products: